EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole

Peter A Fasching, Carolin C Hack, Naiba Nabieva, Nicolai Maass, Bahriye Aktas, Sherko Kümmel, Christoph Thomssen, Christopher Wolf, Hans-Christian Kolberg, Cosima Brucker, Wolfgang Janni, Peter Dall und 30 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Peter A Fasching und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erla…. Hauptthemen laut MEDLINE: Breast Neoplasms, Letrozole, Patient Selection, Postmenopause. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, Novartis Pharma GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLetrozolePatient SelectionPostmenopauseAgedAged, 80 and overFemaleHumansMiddle AgedChemotherapy, AdjuvantCyclin-Dependent Kinase 4Disease-Free SurvivalErb-b2 Receptor Tyrosine KinasesPrognosisReceptors, EstrogenClinical Trials, Phase IV as Topic

Stichwörter der Autor:innen

Aromatase inhibitorsCDK4/6 inhibitorsEarly breast cancerHormone therapyLetrozolePrognosis

Substanzen

Cyclin-Dependent Kinase 4Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanLetrozoleReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Electronic address: peter.fasching@u…
  • Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Gynecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Department of Gynecology, University Hospital Leipzig, Leipzig, Germany.
  • Interdisziplinäres Brustzentrum an den Kliniken Essen-Mitte, Essen, Germany.
  • Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.

Förderung

  • Novartis
  • Novartis Pharma GmbH

Zitieren

APA

Fasching, P. A., Hack, C. C., Nabieva, N., Maass, N., Aktas, B., Kümmel, S., Thomssen, C., Wolf, C., Kolberg, H. C., Brucker, C., Janni, W., Dall, P., Schneeweiss, A., Marme, F., Sütterlin, M. W., Ruebner, M., Theuser, A. K., Kellner, S., Hofmann, N. M., …, & Häberle, L. (2024). Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114239

Vancouver

Fasching PA, Hack CC, Nabieva N, Maass N, Aktas B, Kümmel S, et al. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114239

BibTeX
@article{Fasching2024,
  author = {Fasching, Peter A and Hack, Carolin C and Nabieva, Naiba and Maass, Nicolai and Aktas, Bahriye and Kümmel, Sherko and Thomssen, Christoph and Wolf, Christopher and Kolberg, Hans-Christian and Brucker, Cosima and Janni, Wolfgang and Dall, Peter and Schneeweiss, Andreas and Marme, Frederik and Sütterlin, Marc W and Ruebner, Matthias and Theuser, Anna-Katharin and Kellner, Sara and Hofmann, Nadine M and Böhm, Sybille and Almstedt, Katrin and Lück, Hans-Joachim and Schmatloch, Sabine and Kalder, Matthias and Uleer, Christoph and Jurhasz-Böss, Ingolf and Hanf, Volker and Jackisch, Christian and Müller, Volkmar and Rack, Brigitte and Belleville, Erik and Wallwiener, Diethelm and Rody, Achim and Rauh, Claudia and Bayer, Christian M and Uhrig, Sabrina and Goossens, Chloë and Huebner, Hanna and Brucker, Sara Y and Hein, Alexander and Fehm, Tanja N and Häberle, Lothar},
  title = {Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114239}
}
Kostenlos starten →